The growing complexity of oncology drug development is driving biopharmas to transform their portfolios and partnerships and rethink their approach to market leadership.
Oncology R&D driving strategic transformation
Japan: leading the way in regenerative medicine
Putting China's capital to work in the West
Streamlining drug development — at scale
Augmenting R&D with artificial intelligence
Embedding digital into pharma's DNA
Value-based healthcare and Value Labs
Life sciences dealmaking expected to continue
Australia’s diverted profits tax
Finding sustainability in biotechnology, pharmaceutical and medical technology
Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.
Our Global Life Sciences Network brings together a worldwide team of professionals to help you achieve your potential.
We cover key issues in these areas:
More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world.
But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges.
We have been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry.
We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals.
So it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.
Take a closer look:
Connect with us
Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.
How will IFRS 10 and IFRS 11 impact collaboration arrangements in the life sciences industry? We explain.
Have investor-friendly capital allocation and new competitors upended the world order in M&A? Find out how the biopharma sector is facing this challenge.